


Claims

We claim:

1. A compound of formula (I)



wherein

R^1 is the OH or NHOH;

R^2 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted with one or more substituents selected from R^6 , W and WR^6); and


R^3 is H or alkyl;

or R^2 , R^3 and the carbon atom to which they are attached together represent a carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6 , W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9 , CO_2R^{14} , COR^{10} , $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent $C=O$;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3 , OR^9 , COR^{10} , $S(O)_qR^{10}$, CO_2R^{14} , $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9 , COR^{10} , CO_2R^{15} , $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, $=O$, $=NOR^{10}$, succinimido or the group



R^7 and R^8 , which may be the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3 , CHF_2 , CH_2F , cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12} , $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13} ;

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q$ -, $-N(R^{11})$ -, $-N(R^{11})C(R^{16})_2$ -, $-S(O)_qC(R^{16})_2$ -, $-C(R^{16})_2N(R^{11})$ -, $C(R^{16})_2S(O)_q$ -, $-C(R^{16})=N$ -, $-N=C(R^{16})$ -, $-N(R^{11})SO_2$ -, $-SO_2N(R^{11})$ -, $-N(R^{11})CO$ - or $-CON(R^{11})$ -; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q$ -, $-N(R^{11})$ -, $-N(R^{11})C(R^{16})_2$ -, $-S(O)_qC(R^{16})_2$ -, $-C(R^{16})_2N(R^{11})$ -, $-C(R^{16})_2S(O)_q$ -, $-C(R^{16})=N$ -, $-N=C(R^{16})$ -, $N(R^{11})SO_2$ -,

-SO₂N(R¹¹)-, -N(R¹¹)CO- or -CON(R¹¹)-; and the R¹⁶ groups in C(R¹⁶)₂ may be the same or different;

R¹⁶ is H, alkyl, cycloalkyl, OR⁹, CO₂R¹⁴, COR¹⁰, S(O)_qR¹⁰, CONR⁷R⁸, CN or S(O)_qNR⁷R⁸;

R¹⁷ is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

---- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof.

2. The compound of claim 1, wherein R¹ is NHOH.

3. The compound of claim 1, wherein p is 1; R⁴ is alkyl, cycloalkyl, OR⁹, CO₂ R¹⁴, COR¹⁰, S(O)_qR¹⁰, CONR⁷R⁸, CN or, S(O)_qNR⁷R⁸, or C(R⁴)₂ may represent C=O; R⁶ is not succinimido or the said group; when R⁶ is CO₂R¹⁵, R¹⁵ is H, alkyl or cycloalkyl; and n is 1 or 2.

4. The compound of claim 1, which is selected from

3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)butyric acid,

2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-3-methylbutyric acid,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-

methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-3-methylbutyramide.

5. The compound of claim 1, which is selected from

2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

4-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoyl-ethanesulfonyl]-1,2,3,4-tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,


(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-N-hydroxy-3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonyl)ethyl]-piperidine-1-carboxylic acid benzyl ester.

6. A pharmaceutical composition for use in therapy, comprising a compound of formula (I)



wherein

R^1 is the OH or NHOH;

R^2 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted with one or more substituents selected from R^6 , W and WR^6); and


R^3 is H or alkyl;

or R^2 , R^3 and the carbon atom to which they are attached together represent a carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6 , W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9 , CO_2R^{14} , COR^{10} , $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent $C=O$;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3 , OR^9 , COR^{10} , $S(O)_qR^{10}$, CO_2R^{14} , $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9 , COR^{10} , CO_2R^{15} , $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, $=O$, $=NOR^{10}$, succinimido or the group



R^7 and R^8 , which may be the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3 , CHF_2 , CH_2F , cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl,

heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12} , $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13} ;

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $-N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $-C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

R^{16} is H, alkyl, cycloalkyl, OR^9 , CO_2R^{14} , COR^{10} , $S(O)_qR^{10}$, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$;

R^{17} is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

--- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof;

and a pharmaceutically-acceptable diluent or carrier.

7. The composition of claim 6, wherein wherein R^1 is NHOH.

8. The composition of claim 6, wherein p is 1; R^4 is alkyl, cycloalkyl, OR^9 , CO_2R^{14} , COR^{10} , $S(O)_qR^{10}$, $CONR^7R^8$, CN or, $S(O)_qNR^7R^8$, or $C(R^4)_2$ may represent $C=O$; R^6 is not succinimido or the said group; when R^6 is CO_2R^{15} , R^{15} is H, alkyl or cycloalkyl; and n is 1 or 2.

9. The composition of claim 6, wherein said compound is selected from
3-methyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)butyric acid,
2-(6-methoxy-1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-3-methylbutyric acid,
2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-3-methylbutyramide.

10. The composition of claim 6, wherein said compound is selected from
2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

4-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-

tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoylethanesulfonyl]-
1,2,3,4-tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,


(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid
hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-
3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-
tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonyl)ethyl]-
piperidine-1-carboxylic acid benzyl ester.

11. A method for the treatment of cancer; inflammation; or an autoimmune, infectious
or ocular disease; wherein said method comprises administering to a patient in need of such
treatment an effective amount of a compound of formula (I)



wherein

R¹ is the OH or NHOH;

R² is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl,
cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted
with one or more substituents selected from R⁶, W and WR⁶); and

R³ is H or alkyl;


or R², R³ and the carbon atom to which they are attached together represent a

carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6 , W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9 , CO_2R^{14} , COR^{10} , $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent $C=O$;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3 , OR^9 , COR^{10} , $S(O)_qR^{10}$, CO_2R^{14} , $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9 , COR^{10} , CO_2R^{15} , $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, $=O$, $=NOR^{10}$, succinimido or the group



R^7 and R^8 , which may be the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3 , CHF_2 , CH_2F , cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12} , $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13} ;

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl,

heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, -S(O)_q-, -N(R¹¹)-, -N(R¹¹)C(R¹⁶)₂-, -S(O)_qC(R¹⁶)₂-, -C(R¹⁶)₂N(R¹¹)-, C(R¹⁶)₂S(O)_q-, -C(R¹⁶)=N-, -N=C(R¹⁶)-, -N(R¹¹)SO₂-, -SO₂N(R¹¹)-, -N(R¹¹)CO- or -CON(R¹¹)-, and the R¹⁶ groups in C(R¹⁶)₂ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, -S(O)_q-, -N(R¹¹)-, -N(R¹¹)C(R¹⁶)₂-, -S(O)_qC(R¹⁶)₂-, -C(R¹⁶)₂N(R¹¹)-, -C(R¹⁶)₂S(O)_q-, -C(R¹⁶)=N-, -N=C(R¹⁶)-, N(R¹¹)SO₂-, -SO₂N(R¹¹)-, -N(R¹¹)CO- or -CON(R¹¹)-, and the R¹⁶ groups in C(R¹⁶)₂ may be the same or different;

R^{16} is H, alkyl, cycloalkyl, OR⁹, CO₂R¹⁴, COR¹⁰, S(O)_qR¹⁰, CONR⁷R⁸, CN or S(O)_qNR⁷R⁸;

R^{17} is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

--- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof.

12. The method of claim 11, wherein wherein R¹ is NHOH.

13. The method of claim 11, wherein p is 1; R⁴ is alkyl, cycloalkyl, OR⁹, CO₂R¹⁴, COR¹⁰, S(O)_qR¹⁰, CONR⁷R⁸, CN or S(O)_qNR⁷R⁸, or C(R⁴)₂ may represent C=O; R⁶ is not succinimido or the said group; when R⁶ is CO₂R¹⁵, R¹⁵ is H, alkyl or cycloalkyl; and n is 1 or 2.

14. The method of claim 11, wherein said compound is selected from
3-methyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)butyric acid,
2-(6-methoxy-1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-3-methylbutyric acid,
2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric
acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-
butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-
methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-3-
methylbutyramide.

15. The method of claim 11, wherein said compound is selected from
2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-
tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,
4-(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic
acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-3-
methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-
tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoylethanesulfonyl]-
1,2,3,4-tetrahydro- β -carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

(1,3,4,9-tetrahydro- β -carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid
hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-
3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-
tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro- β -carboline-2-sulfonyl)ethyl]-
piperidine-1-carboxylic acid benzyl ester.